TREM2 and Alzheimer disease: Astrocytosis, measured by glial fibrillary acid protein (GFAP) levels, was reduced across all stages of pathology examined in TREM2 deficient AD mouse models [162, 287], in areas of active demyelination [288] and trended toward a reduction in GFAP area in mice following ischemia [160].